Literature DB >> 23574440

Agonist replacement for stimulant dependence: a review of clinical research.

William W Stoops1, Craig R Rush.   

Abstract

Stimulant use disorders are an unrelenting public health concern worldwide. Agonist replacement therapy is among the most effective strategies for managing substance use disorders including nicotine and opioid dependence. The present paper reviewed clinical data from human laboratory self-administration studies and clinical trials to determine whether agonist replacement therapy is a viable strategy for managing cocaine and/or amphetamine use disorders. The extant literature suggests that agonist replacement therapy may be effective for managing stimulant use disorders, however, the clinical selection of an agonist replacement medication likely needs to be based on the pharmacological mechanism of the medication and the stimulant abused by patients. Specifically, dopamine releasers appear most effective for reducing cocaine use whereas dopamine reuptake inhibitors appear most effective for reducing amphetamine use.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23574440      PMCID: PMC3740019          DOI: 10.2174/138161281940131209142843

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  150 in total

Review 1.  Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence.

Authors:  John Grabowski; James Shearer; John Merrill; S Stevens Negus
Journal:  Addict Behav       Date:  2004-09       Impact factor: 3.913

Review 2.  Pharmacologic management of relapse prevention in addictive disorders.

Authors:  Mehmet Sofuoglu; Thomas R Kosten
Journal:  Psychiatr Clin North Am       Date:  2004-12

3.  Risperidone attenuates the discriminative-stimulus effects of d-amphetamine in humans.

Authors:  Craig R Rush; William W Stoops; Lon R Hays; Paul E A Glaser; Lon S Hays
Journal:  J Pharmacol Exp Ther       Date:  2003-04-03       Impact factor: 4.030

Review 4.  Amphetamine: effects on catecholamine systems and behavior.

Authors:  L S Seiden; K E Sabol; G A Ricaurte
Journal:  Annu Rev Pharmacol Toxicol       Date:  1993       Impact factor: 13.820

5.  Acute behavioral and physiological effects of modafinil in drug abusers.

Authors:  C R Rush; T H Kelly; L R Hays; R W Baker; A F Wooten
Journal:  Behav Pharmacol       Date:  2002-03       Impact factor: 2.293

Review 6.  Bupropion versus selective serotonin-reuptake inhibitors for treatment of depression.

Authors:  C E Nieuwstraten; L R Dolovich
Journal:  Ann Pharmacother       Date:  2001-12       Impact factor: 3.154

7.  Methylphenidate and cocaine have a similar in vivo potency to block dopamine transporters in the human brain.

Authors:  N D Volkow; G J Wang; J S Fowler; M Fischman; R Foltin; N N Abumrad; S J Gatley; J Logan; C Wong; A Gifford; Y S Ding; R Hitzemann; N Pappas
Journal:  Life Sci       Date:  1999       Impact factor: 5.037

8.  Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion and placebo.

Authors:  Frances R Levin; Suzette M Evans; Daniel J Brooks; Aparna S Kalbag; Fatima Garawi; Edward V Nunes
Journal:  Drug Alcohol Depend       Date:  2005-08-15       Impact factor: 4.492

9.  Modafinil does not serve as a reinforcer in cocaine abusers.

Authors:  Suzanne K Vosburg; Carl L Hart; Margaret Haney; Eric Rubin; Richard W Foltin
Journal:  Drug Alcohol Depend       Date:  2009-09-23       Impact factor: 4.492

10.  Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain.

Authors:  N D Volkow; Y S Ding; J S Fowler; G J Wang; J Logan; J S Gatley; S Dewey; C Ashby; J Liebermann; R Hitzemann
Journal:  Arch Gen Psychiatry       Date:  1995-06
View more
  35 in total

1.  Methamphetamine self-administration in humans during D-amphetamine maintenance.

Authors:  Erika Pike; William W Stoops; Lon R Hays; Paul E A Glaser; Craig R Rush
Journal:  J Clin Psychopharmacol       Date:  2014-12       Impact factor: 3.153

2.  Separate and combined effects of gabapentin and [INCREMENT]9-tetrahydrocannabinol in humans discriminating [INCREMENT]9-tetrahydrocannabinol.

Authors:  Joshua A Lile; Michael J Wesley; Thomas H Kelly; Lon R Hays
Journal:  Behav Pharmacol       Date:  2016-04       Impact factor: 2.293

3.  Use of Preclinical Drug vs. Food Choice Procedures to Evaluate Candidate Medications for Cocaine Addiction.

Authors:  Matthew L Banks; Blake A Hutsell; Kathryn L Schwienteck; S Stevens Negus
Journal:  Curr Treat Options Psychiatry       Date:  2015-06

Review 4.  Agonist Medications for the Treatment of Cocaine Use Disorder.

Authors:  S Stevens Negus; Jack Henningfield
Journal:  Neuropsychopharmacology       Date:  2014-12-11       Impact factor: 7.853

5.  Retrospective analysis of health claims to evaluate pharmacotherapies with potential for repurposing: Association of bupropion and stimulant use disorder remission.

Authors:  Emily R Hankosky; Heather M Bush; Linda P Dwoskin; Daniel R Harris; Darren W Henderson; Guo-Qiang Zhang; Patricia R Freeman; Jeffery C Talbert
Journal:  AMIA Annu Symp Proc       Date:  2018-12-05

Review 6.  Pharmacotherapies for decreasing maladaptive choice in drug addiction: Targeting the behavior and the drug.

Authors:  Frank N Perkins; Kevin B Freeman
Journal:  Pharmacol Biochem Behav       Date:  2017-06-27       Impact factor: 3.533

Review 7.  Potential role of N-acetylcysteine in the management of substance use disorders.

Authors:  Erin A McClure; Cassandra D Gipson; Robert J Malcolm; Peter W Kalivas; Kevin M Gray
Journal:  CNS Drugs       Date:  2014-02       Impact factor: 5.749

8.  Pharmacotherapeutic strategies for treating cocaine use disorder-what do we have to offer?

Authors:  Laura Brandt; Thomas Chao; Sandra D Comer; Frances R Levin
Journal:  Addiction       Date:  2020-09-28       Impact factor: 6.526

9.  Effects of L-methamphetamine treatment on cocaine- and food-maintained behavior in rhesus monkeys.

Authors:  Stephen J Kohut; Jack Bergman; Bruce E Blough
Journal:  Psychopharmacology (Berl)       Date:  2015-12-29       Impact factor: 4.530

10.  Relationship between oral D-amphetamine self-administration and ratings of subjective effects: do subjective-effects ratings correspond with a progressive-ratio measure of drug-taking behavior?

Authors:  B Levi Bolin; Anna R Reynolds; William W Stoops; Craig R Rush
Journal:  Behav Pharmacol       Date:  2013-09       Impact factor: 2.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.